Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2025-12-28 @ 11:20 PM
Study NCT ID:
NCT05993234
Status:
RECRUITING
Last Update Posted:
2025-12-11
First Post:
2023-08-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Sponsor:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-05
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-02
First Submit QC Date:
None
Study First Post Date:
2023-08-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-04
Last Update Post Date:
2025-12-11
Last Update Post Date Type:
ESTIMATED